Toll-like receptor 7 agonist, Imiquimod, inhibits oral squamous carcinoma cells through apoptosis and necrosis

被引:42
|
作者
Ahn, Mee-Young [2 ,3 ]
Kwon, Seong-Min [2 ,3 ]
Cheong, Hak Hyun [2 ,3 ]
Park, Jong-Hwan [4 ]
Lee, Jun [5 ]
Min, Seung-Ki [5 ]
Ahn, Sang-Gun [2 ,3 ]
Yoon, Jung-Hoon [1 ]
机构
[1] Wonkwang Univ, Dept Oral & Maxillofacial Pathol, Coll Dent,Wonkwang Bone Regenerat Res Inst, Daejeon Dent Hosp, Taejon 302120, South Korea
[2] Chosun Univ, Dept Pathol, Kwangju, South Korea
[3] Chosun Univ, Res Ctr Oral Dis Regulat Aged, Sch Dent, Kwangju, South Korea
[4] Konyang Univ, Dept Biochem, Coll Med, Taejon, South Korea
[5] Wonkwang Univ, Dept Oral & Maxillofacial Surg, Coll Dent,Wonkwang Bone Regenerat Res Inst, Daejeon Dent Hosp, Taejon 302120, South Korea
基金
新加坡国家研究基金会;
关键词
apoptosis; imiquimod; necrosis; oral sqaumous cell carcinoma; toll-like receptor 7; CANCER-THERAPY; INFLAMMATION; RECOGNITION; HEPATOCYTES; INTERFERON; INDUCTION; AUTOPHAGY; DEATH; CREAM; HMGB1;
D O I
10.1111/j.1600-0714.2012.01158.x
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
J Oral Pathol Med (2012) 41: 540546 Background: Toll-like receptor (TLR) agonists have anticancer effect by inducing apoptosis or activating immune cells. In this study, we investigated whether imiquimod, TLR7 agonist, inhibits the proliferation of oral cancer cells. Methods: Toll-like receptor 7 expression and IL-6/8 production by imiquimod were examined using RT-PCR and Enzyme-linked immunosorbent assay, respectively. Cell viability was examined by MTT assay. To examine apoptotic cell death, Annexin V/PI staining for flow cytometry and Western blot analysis were performed. Necrotic cell death was determined by leakage of lactate dehydrogenase (LDH), HMGB1, and PI staining in imiquimod-treated oral squamous cell carcinoma (OSCC) cells. Results: Toll-like receptor7 mRNA was expressed in OSCC cells. Imiquimod induced IL-6 and IL-8 production in OSCC cells, suggesting the functional expression of TLR7. Imiquimod inhibited cells proliferation in a dose-dependent manner. The ratio of annexin V-positive cells and cleaved caspase-3/7 was increased by imiquimod treatment in OSCC cells, suggesting that imiquimod-induced cell death in OSCC cells may be owing to apoptosis. In addition, LDH secretion and PI staining were detected in OSCC cells treated with imiquimod, showing that imiquimod also induced necrotic cell death in the OSCC cells. Conclusions: Imiquimod inhibited effectively the growth of OSCC cells by inducing apoptosis and necrosis.
引用
收藏
页码:540 / 546
页数:7
相关论文
共 50 条
  • [1] Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo
    Luo, Qingqiong
    Hu, Shuiqing
    Yan, Ming
    Sun, Zujun
    Chen, Wantao
    Chen, Fuxiang
    INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2012, 44 (08) : 1266 - 1275
  • [2] Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma
    Yoon, Angela J.
    Carvajal, Richard D.
    Graboyes, Evan M.
    Kaczmar, John M.
    Albergotti, William G.
    Kejner, Alexandra E.
    Troob, Scott H.
    Philipone, Elizabeth
    Anoma, Jean-Sebastien
    Armeson, Kent E.
    Hill, Elizabeth G.
    Richardson, Mary S.
    Woods, Tina R.
    Chera, Bhishamjit S.
    Nourollah-Zadeh, Farzad
    Lee, Byung J.
    Pandruvada, Subramanya
    Kourtidis, Antonis
    Kingsley, Christina
    O'Quinn, Elizabeth C.
    Mills, Stephanie
    Jordan, Victoria C.
    Spencer, Mike
    Fails, Danielle
    Mckee, Trevor D.
    Zaidi, Mark
    Brisendine, Alan
    Horn, Shane
    Mehrotra, Shikhar
    Ogretmen, Besim
    Newman, Jason G.
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [3] Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures
    Meyer, T
    Nindl, I
    Schmook, T
    Ulrich, C
    Sterry, W
    Stockfleth, E
    BRITISH JOURNAL OF DERMATOLOGY, 2003, 149 : 9 - 13
  • [4] The Toll-like receptor 7 agonist imiquimod increases ethanol self-administration and induces expression of Toll-like receptor related genes
    Lovelock, Dennis F.
    Liu, Wen
    Langston, Sarah E.
    Liu, Jiaqi
    Van Voorhies, Kalynn
    Giffin, Kaitlin A.
    Vetreno, Ryan P.
    Crews, Fulton T.
    Besheer, Joyce
    ADDICTION BIOLOGY, 2022, 27 (03)
  • [5] Activation of Toll-like receptor 7 inhibits the proliferation and migration, and induces the apoptosis of pancreatic cancer cells
    Zou, Bing-Bing
    Wang, Fang
    Li, Lei
    Cheng, Feng-Wei
    Jin, Rui
    Luo, Xin
    Zhu, Li-Xin
    Geng, Xiaoping
    Zhang, Sheng-Quan
    MOLECULAR MEDICINE REPORTS, 2015, 12 (04) : 6079 - 6085
  • [6] IMIQUIMOD, A TOLL-LIKE RECEPTOR 7 LIGAND, INHIBITS AIRWAY REMODELLING IN A MURINE MODEL OF CHRONIC ASTHMA
    Du, Qiang
    Zhou, Lin-Fu
    Chen, Zhen
    Gu, Xiao-Yan
    Huang, Mao
    Yin, Kai-Sheng
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2009, 36 (01): : 43 - 48
  • [7] Toll-like receptor 7 stimulation by imiquimod induces macrophage autophagy and inflammation in atherosclerotic plaques
    De Meyer, Inge
    Martinet, Wim
    Schrijvers, Dorien M.
    Timmermans, Jean-Pierre
    Bult, Hidde
    De Meyer, Guido R. Y.
    BASIC RESEARCH IN CARDIOLOGY, 2012, 107 (03)
  • [8] Toll-like receptor 2 activation implicated in oral squamous cell carcinoma development
    Ikehata, Naoki
    Takanashi, Masakatsu
    Satomi, Takafumi
    Watanabe, Masato
    Hasegawa, On
    Kono, Michihide
    Enomoto, Ai
    Chikazu, Daichi
    Kuroda, Masahiko
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 495 (03) : 2227 - 2234
  • [9] Active Toll-like receptor-7 triggering of chronic lymphocytic leukemia B-cells by imiquimod
    Chen, Min
    Bittencourt, Marcelo de Carvalho
    Feugier, Pierre
    Faure, Gilbert C.
    Bene, Marie C.
    LEUKEMIA & LYMPHOMA, 2012, 53 (04) : 739 - 742
  • [10] Expression of Toll-like receptors in oral squamous cell carcinoma
    Rusanen, Peter
    Marttila, Emilia
    Amatya, Sajeen Bahadur
    Hagstroem, Jaana
    Uittamo, Johanna
    Reunanen, Justus
    Rautemaa-Richardson, Riina
    Salo, Tuula
    PLOS ONE, 2024, 19 (04):